Testing a new COVID-19 vaccine booster for safety and immune response

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the safety and immunogenicity of the CD40.RBDv bivalent COVID-19 vaccine, with and without an adjuvant, as a booster in healthy volunteers. Participants will be randomly assigned to receive either the CD40.RBDv vaccine or an approved mRNA vaccine, with different dosing regimens across four cohorts. The study aims to assess the vaccine's safety profile and its ability to elicit an immune response. The trial is structured in two parts, with follow-up assessments to determine the need for additional doses.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Healthy volunteers Age ≥18 and \<85
* Able to understand and comply with planned study procedures and sign an informed consent before performance of any study-related screening procedures
* Who has received a primary series of vaccination and ≥ 1 booster(s) of COVID-19 mRNA vaccination(s) with the last boost at least 6 months prior to the inclusion in the study
* Subjects has adequate organ functions, evidenced by normal ALT, AST, and alkaline phosphatase
* Normal haematology lab values
* Negative virology assessment
* Normal Urine testing
* Volunteers must meet the eligibility criteria in the approved package labelling of the active comparator
* For women of childbearing potential: use of an effective contraceptive method and negative pregnancy test. For male participants, use of an effective method of contraception with their partner

Exclusion Criteria:

* Acute febrile infection within the previous 72 hours and/or presenting symptoms suggestive of COVID-19 or SARS CoV 2 infection within the previous 28 days
* Immunosuppressive medications received within last three months before first IMP administration or within 6 months for chemotherapies
* Immunoglobulins within 90 days before first IMP administration
* Blood products within 120 days before first IMP administration
* Any medical condition, such as cancer, that might impair the immune response
* Use of any experimental therapy
* Intent to participate in another study of an investigational research agent within 4 weeks prior to the enrolment visit or until the end of the study
* Currently pregnant or breastfeeding
* History of severe adverse events following vaccine administration
* Any bleeding disorder considered as a contraindication to an intramuscular injection
* A condition that requires active medical intervention or monitoring to avert grave danger to Asthma other than mild, well-controlled asthma.
* Hypertension
* BMI ≥ 40 kg/m2; ≤ 18 kg/m2; or BMI ≥ 35 kg/m2 with 2 or more of the following: age \> 45, current smoker, known hyperlipidemia, blood pressure is defined as consistently ≥ 140 mm Hg systolic and ≥ 90 mm Hg diastolic
* Malignancy
* Asplenia
* Seizure disorder
* History of hereditary angioedema acquired angioedema, or idiopathic angioedema
* History of myocarditis, pericarditis, cardiomyopathy, congestive heart failure with permanent sequelae, clinically significant arrhythmia (including arrhythmia requiring medication, treatment, or clinical follow-up
* History of autoimmune disease
* Any medical, occupational, or other condition that, in the judgment of the investigator, would interfere with or serve as a contraindication to protocol adherence
* Psychiatric condition that precludes compliance with the protocol.
* Live attenuated vaccines received within 30 days before first IMP administration or scheduled within 28 days after one of the last injection according to the protocol
* Vaccines that are not live attenuated vaccines and were received within 21 days prior to first IMP administration
* Allergy treatment with antigen injections within 30 days before first IMP administration and until the end of the study

Where it's running

• Hopital Henri Mondor
  Créteil, France Recruiting
• Hôpital Cochin
  Paris, France Recruiting

Study contacts

• Study coordinator: Yves Levy, MD
• Email: yves.levy@aphp.fr
• Phone: +33149814442

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) in Adults

  This study tests and compares the immune responses and tolerability of the latest COVID-19 vaccines from Novavax and Pfizer/BioNTech in adults at risk for severe COVID-19.

  Recruiting Phase 4 Henry M. Jackson Foundation for the Advancement of Military Medicine · Bethesda, Maryland · NCT07287137

• Omicron-based COVID-19 vaccine with Matrix-M given as a single dose in older adults and high-risk individuals

  A single-dose Omicron-subvariant vaccine with Matrix-M is tested to see if it is safe and can induce an immune response in adults 65+ and in younger adults with conditions that raise the risk of severe COVID-19, who were previously vaccinated.

  Recruiting at 20 sites Phase 4 Sanofi · Fair Oaks, California and 19 other locations · NCT07861542

• Secutrelvir for nonhospitalized COVID-19 in teens and adults

  This study tests whether secutrelvir can help nonhospitalized people with COVID-19 see faster symptom relief compared with a placebo.

  Recruiting Phase 3 Shionogi Inc. · Multiple Locations · NCT07746544

• Virological Monitoring of Seasonal Respiratory Infections in France

  This project tests how often common respiratory viruses show up in patients seen by primary care doctors in metropolitan France during the fall and winter.

  Recruiting Institut National de la Santé Et de la Recherche Médicale, France · Paris · NCT07599449

• COVID-19 Registry at San Matteo (SMACORE) - patient-matching observational registry

  This registry tests how COVID-19 patients are being treated and progress across San Matteo in Pavia to understand patterns and outcomes.

  Recruiting Fondazione IRCCS Policlinico San Matteo di Pavia · Pavia · NCT07597876

• MDX2301 in healthy adults and adults at higher risk for severe COVID-19

  This study will try single and repeat doses of MDX2301 given by IV, IM, or SC to see if they are safe and trigger neutralizing activity in healthy adults and adults at higher risk for severe COVID-19.

  Recruiting at 2 sites Phase 1 ModeX Therapeutics, An OPKO Health Company · Las Vegas, Nevada and 1 other locations · NCT07445971

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.